文献速递生殖医学

体外受精卵巢刺激高、低卵巢反应预后模型的性能

Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF.
PubMed 文献 · Hum Reprod · 2018-01-01

前瞻性多中心观察性队列研究中,211例体重>60 kg不孕女性接受150 μg corifollitropin alfa/GnRH拮抗剂方案刺激,验证既往建立的低反应和高反应预测模型表现良好,低反应AUC 0.8879,高反应AUC 0.8909;新简化模型低反应AUC 0.8920,高反应AUC 0.8976。

要点

  • 既往建立的低、高卵巢反应预测模型在本数据集表现良好,AMH最为重要。
  • 新简化低反应模型仅用对数转换AMH和年龄,AUC 0.8920且AICc最低。
  • 作者建议高反应预测简化模型使用AMH、FSH和AFC,AUC 0.8976。

核心结论

  • 使用150 μg corifollitropin alfa固定多剂量GnRH拮抗剂方案时,可用逻辑回归模型有效预测卵巢反应,AMH最为重要。

研究设计与样本

  • 前瞻性、多中心(n=5)、多国、研究者发起的观察性队列研究,纳入211例体重>60 kg的不孕女性。

主要发现

  • 既往低反应预测模型AUC 0.8879(95%CI:0.8185-0.9573),高反应预测模型AUC 0.8909(95%CI:0.8251-0.9568)。
  • 新简化低反应模型(对数转换AMH和年龄)AUC 0.8920(95%CI:0.8237-0.9603),AICc在所有比较模型中最低。
  • 作者建议的高反应简化模型(AMH、FSH和AFC)AUC 0.8976(95%CI:0.8206-0.9746)。

关键数值与推荐

  • 低卵巢反应定义为获卵数<6个,高卵巢反应定义为获卵数>18个。

临床怎么用

  • 作者认为,使用corifollitropin alfa进行卵巢刺激的患者选择应利用已建立的反应预测模型。
  • 作者指出,其临床影响需在未來研究中评估。

局限性

  • 所有分析均基于体重>60 kg女性的数据。
  • 新开发的简化模型可能过拟合,需在进一步独立数据集中测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the performance of previously established regression models in predicting low and high ovarian response to 150 μg corifollitropin alfa/GnRH-antagonist ovarian stimulation in an independent dataset? SUMMARY ANSWER: The outcome of ovarian stimulation with 150 μg corifollitropin alfa in a fixed, multiple dose GnRH-antagonist protocol can be validly predicted using logistic regression models with AMH being of paramount importance. WHAT IS KNOWN ALREADY: Predictors of ovarian response have been identified in FSH/GnRH agonist protocols as well as ovarian stimulation with corifollitropin alfa/GnRH-antagonist. Multivariable response models have been established already, however, external validation of model performance has so far been lacking. STUDY DESIGN, SIZE, DURATION: Data from a prospective, multi-centre (n = 5), multi-national, investigator-initiated, observational cohort study were analysed. Infertile women (n = 211), body weight >60 kg, were undergoing ovarian stimulation with 150 μg corifollitropin alfa in a GnRH-antagonist multiple dose protocol for transvaginal oocyte retrieval for IVF. Demographic, sonographic and endocrine parameters were prospectively assessed on cycle Day 2 or 3 of spontaneous menstruation before ovarian stimulation. Main outcomes were low (<6 oocytes) and high (>18 oocytes) ovarian response. PARTICIPANTS/MATERIALS, SETTING, METHODS: Firstly, previously established prediction models for low ovarian response (LOR) and high ovarian response (HOR) were tested using the original parameters. Secondly, re-estimated parameters generated from the present data were tested on the established models. Thirdly, for the development of new predictive models of both LOR and HOR, several logistic regression models were estimated. Resulting prediction models were compared by means of the area under the receiver operating characteristic curve (AUC) and bias-corrected Akaike's Information Criterion (AICc) to identify the most reasonable model for each scenario. MAIN RESULTS AND THE ROLE OF CHANCE: The previously established prediction models for low and high response performed remarkably well on this dataset (low response AUC 0.8879 (95% CI: 0.8185-0.9573) and high response AUC 0.8909 (95% CI: 0.8251-0.9568)). A newly developed simplified model for LOR with log-transformed AMH values and only age as another covariate showed an AUC of 0.8920 (95% CI: 0.8237-0.9603) with the lowest AICc of all models compared. For predicting HOR, we suggest a simplified model using AMH, FSH and AFC (AUC of 0.8976, 95% CI: 0.8206-0.9746). LIMITATIONS, REASONS FOR CAUTION: All analyses were done on data from women with a body weight >60 kg. The newly developed simplified models may suffer from overfitting and need to be tested in further independent data sets. WIDER IMPLICATIONS OF THE FINDINGS: Patient selection for ovarian stimulation with corifollitropin alfa should utilize established response prediction models. The clinical impact of this needs to be evaluated in future studies. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by university funds. M.O.S., T.L. and I.R.K. have nothing to declare. G.G. has received personal fees and non-financial support from MSD, Ferring, Merck-Serono, Finox, TEVA, IBSA, Glycotope, Abbott, Marckryl Pharma, VitroLife, NMC Healthcare, ReprodWissen, ZIVA and BioSilu. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Scheinhardt MO, Lerman T, König IR, et al. Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF. Hum Reprod. 2018. PMID: 30007353. doi:10.1093/humrep/dey236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。